Press release
Global HER2 Inhibitors Market 2024 Mega Trends, Industry Growth, Future Outlook And Forecast To 2033
HER2 Inhibitors Market
The Business Research Company offers in-depth market insights through HER2 Inhibitors Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.
Market Size And Growth Forecast:
The her2 inhibitors market size has grown strongly in recent years. It will grow from $8.77 billion in 2023 to $9.64 billion in 2024 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to biotechnological advances, clinical trial success, shift in treatment paradigm, research and development investments, patient outcomes improvement.
The her2 inhibitors market size is expected to see strong growth in the next few years. It will grow to $13.61 billion in 2028 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to patient-centric care models, regulatory changes and approvals, drug resistance management, global market penetration, expanded indications, precision oncology adoption. Major trends in the forecast period include patient advocacy and awareness, clinical trials and research, early detection and diagnosis, precision medicine and biomarker testing, adjuvant and neoadjuvant therapy.
Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=3396&type=smp
Market Segmentation:
The her2 inhibitors market covered in this report is segmented -
1) By Treatment: Monotherapy, Combination Therapy
2) By Application: Squamous Cell Carcinoma, Adenocarcinoma, Large Cell Carcinoma, Breast Cancer, Other Applications
3) By End User: Hospitals, Clinics, Other End Users
Major Driver - Increasing Incidence Of Breast Cancer Cases Fuels The Her-2 Inhibtors Market Growth
The rise in the number of breast cancer cases across the globe is likely to contribute to the growth of the HER-2 inhibitors market during the forecast period. For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. Therefore, the rise in the breast cancer incidence rate globally is anticipated to boost the demand for the HER-2 inhibitors market over the forthcoming years.
Competitive Landscape:
Major companies operating in the her2 inhibitors market report are Pfizer Inc., Johnson & Johnson Services Inc., F Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly International Corp., Gilead Sciences Inc., C.H. Boehringer Sohn AG & Co. KG, Applied Molecular Genetics Inc., Viatris Inc. US, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Catalent Inc., Ipsen SA, Cipla Limited, the Pierre Fabre Group, Biocon Biopharmaceuticals Pvt. Ltd., Innovent Biologics Inc., Halozyme Therapeutics Inc., Seattle Genetics Inc., Zymeworks Inc., Puma Biotechnology Inc., MacroGenics Inc., Mersana Therapeutics Inc., Cellestia Biotech AG
Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/her2-inhibitor-global-market-report
Top Trend - Increasing Focus On Developing Treatment Forher2-Low Breast Cancerto Gain A Competitive Edge
Major companies operating in the HER2 inhibitor market are focused on developing treatments for HER2-low breast cancer to gain a competitive edge in the market. HER2-low breast cancer is a newly defined subset of HER2-negative breast cancer, which includes tumors that do not overexpress or make too many copies of the HER2 protein. For instance, in August 2022, AstraZeneca PLC, a UK-based pharmaceutical and biotechnology company, the U.S. Food and Drug Administration (FDA) approved Enhertu (fam-trastuzumab deruxtecan-nxki) as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer. Enhertu is prescribed via intravenous infusion to address HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer in adults who have undergone prior metastatic chemotherapy or experienced disease recurrence within six months of completing adjuvant chemotherapy.
The Table Of Content For The Market Report Include:
1. Executive Summary
2. HER2 Inhibitors Market Characteristics
3. HER2 Inhibitors Market Trends And Strategies
4. HER2 Inhibitors Market - Macro Economic Scenario
5. HER2 Inhibitors Market Size And Growth
…..
27. HER2 Inhibitors Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global HER2 Inhibitors Market 2024 Mega Trends, Industry Growth, Future Outlook And Forecast To 2033 here
News-ID: 3416023 • Views: …
More Releases from The Business research company
Evolving Market Trends In The Integrated Geophysical Services Industry: Enhancin …
The Integrated Geophysical Services Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Integrated Geophysical Services Market Size During the Forecast Period?
The integrated geophysical services market has experienced consistent growth in recent years, expected to rise from $2.35 billion in 2024 to…
Global HR Advisory Services Market: Key Trends, Market Share, Growth Drivers, An …
The HR advisory services market report describes and explains the HR advisory services market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global HR advisory services market reached a value of nearly $155.74 billion in 2024, having grown at a compound annual growth rate (CAGR) of 4.22% since…
High Voltage Aluminium Electrolytic Capacitors Global Market Report 2025: Size, …
The high voltage aluminum electrolytic capacitors report describes and explains the high voltage aluminum electrolytic capacitors market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global high voltage aluminum electrolytic capacitors market reached a value of nearly $4.10301 billion in 2024, having grown at a compound annual growth…
Global Vertical Market Software Market: Key Trends, Market Share, Growth Drivers …
The vertical market software report describes and explains the vertical market software market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global vertical market software market reached a value of nearly $152.61027 billion in 2024, having grown at a compound annual growth rate (CAGR) of 12.11% since 2019.…
More Releases for HER2
Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative T …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Expected HER2-Positive Breast Cancer Market Size During the Forecast Period?
Over the past few years, there has been a noteworthy expansion in the HER2-positive breast cancer market. The market, which is projected to increase from $10.21 billion in 2024 to $10.96 billion in the following year, predicts a compound annual growth…
HER2 Inhibitors: Advancing Breast Cancer Treatments
"The Business Research Company recently released a comprehensive report on the Global HER2 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
HER2 Positive Breast Cancer Pipeline Drugs 2024
DelveInsight's, "HER2 Positive Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
HER2 Inhibitors: Targeted Therapies Transforming Cancer Treatment
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period.
Global HER2 Inhibitors Market Scope and Market Size
The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyze…
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis.
Although more drug…
HER2 negative Breast Cancer Pipeline involves 85+ key companies continuously wor …
DelveInsight's HER2 negative Breast Cancer Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the HER2 negative Breast Cancer pipeline domain.
Some of the essential takeaways from the HER2 negative Breast Cancer Pipeline report:
• DelveInsight's HER2 negative Breast Cancer Pipeline analysis depicts a robust space with…
